Last reviewed · How we verify

NCT05859958

ABO Blood Group Type Association With COVID-19 Severity

Completed Last updated 26 May 2023
What this trial tests

trial testing No Intervention in COVID-19 in 599 participants. Completed in 10 May 2023.

Timeline
10 November 2022
Primary endpoint
10 May 2023
10 May 2023

Quick facts

Lead sponsorArrowhead Regional Medical Center
StatusCompleted
Study typeOBSERVATIONAL
Enrollment599
Start date10 November 2022
Primary completion10 May 2023
Estimated completion10 May 2023
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Arrowhead Regional Medical Center

Who can join

Adults 18 to 90, any sex, with COVID-19 or Blood Group Antigen Abnormality. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The COVID-19 pandemic has caused a significant healthcare burden and remains a heavily researched disease entity. Originating in Wuhan, China in late 2019, SARS-CoV-2 has infected over 600 million individuals worldwide. ABO blood groups have been known to increase the human body's susceptibility to different pathogens, such as hepatitis B virus, MERS-COV, SARS-COV, norovirus, and malaria, to name a few. As such, the association of ABO blood groups and COVID-19 infection and disease severity has come into question.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of No Intervention

Trials testing the same drug.

Other recruiting trials for COVID-19

Currently open trials in the same condition.

Other Arrowhead Regional Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05859958.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing